Post-acute sequelae of COVID-19 in a non-hospitalized cohort: Results from the Arizona CoVHORT.
Clinical presentation, outcomes, and duration of COVID-19 has ranged dramatically. While some individuals recover quickly, others suffer from persistent symptoms, collectively known as long COVID, or post-acute sequelae of SARS-CoV-2 (PASC). Most PASC research has focused on hospitalized COVID-19 pa...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/3684ccb801e947c19566e5a9f454dd69 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:3684ccb801e947c19566e5a9f454dd69 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:3684ccb801e947c19566e5a9f454dd692021-12-02T20:06:22ZPost-acute sequelae of COVID-19 in a non-hospitalized cohort: Results from the Arizona CoVHORT.1932-620310.1371/journal.pone.0254347https://doaj.org/article/3684ccb801e947c19566e5a9f454dd692021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0254347https://doaj.org/toc/1932-6203Clinical presentation, outcomes, and duration of COVID-19 has ranged dramatically. While some individuals recover quickly, others suffer from persistent symptoms, collectively known as long COVID, or post-acute sequelae of SARS-CoV-2 (PASC). Most PASC research has focused on hospitalized COVID-19 patients with moderate to severe disease. We used data from a diverse population-based cohort of Arizonans to estimate prevalence of PASC, defined as experiencing at least one symptom 30 days or longer, and prevalence of individual symptoms. There were 303 non-hospitalized individuals with a positive lab-confirmed COVID-19 test who were followed for a median of 61 days (range 30-250). COVID-19 positive participants were mostly female (70%), non-Hispanic white (68%), and on average 44 years old. Prevalence of PASC at 30 days post-infection was 68.7% (95% confidence interval: 63.4, 73.9). The most common symptoms were fatigue (37.5%), shortness-of-breath (37.5%), brain fog (30.8%), and stress/anxiety (30.8%). The median number of symptoms was 3 (range 1-20). Amongst 157 participants with longer follow-up (≥60 days), PASC prevalence was 77.1%.Melanie L BellCollin J CatalfamoLeslie V FarlandKacey C ErnstElizabeth T JacobsYann C KlimentidisMegan JehnKristen Pogreba-BrownPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 8, p e0254347 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Melanie L Bell Collin J Catalfamo Leslie V Farland Kacey C Ernst Elizabeth T Jacobs Yann C Klimentidis Megan Jehn Kristen Pogreba-Brown Post-acute sequelae of COVID-19 in a non-hospitalized cohort: Results from the Arizona CoVHORT. |
| description |
Clinical presentation, outcomes, and duration of COVID-19 has ranged dramatically. While some individuals recover quickly, others suffer from persistent symptoms, collectively known as long COVID, or post-acute sequelae of SARS-CoV-2 (PASC). Most PASC research has focused on hospitalized COVID-19 patients with moderate to severe disease. We used data from a diverse population-based cohort of Arizonans to estimate prevalence of PASC, defined as experiencing at least one symptom 30 days or longer, and prevalence of individual symptoms. There were 303 non-hospitalized individuals with a positive lab-confirmed COVID-19 test who were followed for a median of 61 days (range 30-250). COVID-19 positive participants were mostly female (70%), non-Hispanic white (68%), and on average 44 years old. Prevalence of PASC at 30 days post-infection was 68.7% (95% confidence interval: 63.4, 73.9). The most common symptoms were fatigue (37.5%), shortness-of-breath (37.5%), brain fog (30.8%), and stress/anxiety (30.8%). The median number of symptoms was 3 (range 1-20). Amongst 157 participants with longer follow-up (≥60 days), PASC prevalence was 77.1%. |
| format |
article |
| author |
Melanie L Bell Collin J Catalfamo Leslie V Farland Kacey C Ernst Elizabeth T Jacobs Yann C Klimentidis Megan Jehn Kristen Pogreba-Brown |
| author_facet |
Melanie L Bell Collin J Catalfamo Leslie V Farland Kacey C Ernst Elizabeth T Jacobs Yann C Klimentidis Megan Jehn Kristen Pogreba-Brown |
| author_sort |
Melanie L Bell |
| title |
Post-acute sequelae of COVID-19 in a non-hospitalized cohort: Results from the Arizona CoVHORT. |
| title_short |
Post-acute sequelae of COVID-19 in a non-hospitalized cohort: Results from the Arizona CoVHORT. |
| title_full |
Post-acute sequelae of COVID-19 in a non-hospitalized cohort: Results from the Arizona CoVHORT. |
| title_fullStr |
Post-acute sequelae of COVID-19 in a non-hospitalized cohort: Results from the Arizona CoVHORT. |
| title_full_unstemmed |
Post-acute sequelae of COVID-19 in a non-hospitalized cohort: Results from the Arizona CoVHORT. |
| title_sort |
post-acute sequelae of covid-19 in a non-hospitalized cohort: results from the arizona covhort. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2021 |
| url |
https://doaj.org/article/3684ccb801e947c19566e5a9f454dd69 |
| work_keys_str_mv |
AT melanielbell postacutesequelaeofcovid19inanonhospitalizedcohortresultsfromthearizonacovhort AT collinjcatalfamo postacutesequelaeofcovid19inanonhospitalizedcohortresultsfromthearizonacovhort AT leslievfarland postacutesequelaeofcovid19inanonhospitalizedcohortresultsfromthearizonacovhort AT kaceycernst postacutesequelaeofcovid19inanonhospitalizedcohortresultsfromthearizonacovhort AT elizabethtjacobs postacutesequelaeofcovid19inanonhospitalizedcohortresultsfromthearizonacovhort AT yanncklimentidis postacutesequelaeofcovid19inanonhospitalizedcohortresultsfromthearizonacovhort AT meganjehn postacutesequelaeofcovid19inanonhospitalizedcohortresultsfromthearizonacovhort AT kristenpogrebabrown postacutesequelaeofcovid19inanonhospitalizedcohortresultsfromthearizonacovhort |
| _version_ |
1718375354415972352 |